University of Liège

Amélie Lamarcq

University of Liège
Student

Amélie Lamarcq obtained her First State Examination at the University of Freiburg in 2019, where she opted for the business law specialization. She is currently pursuing a bilingual (French and English) LL.M. in European Competition and IP Law at the University of Liège.

Linked authors

University of Liège
University of Liège
University of Liège
University of Liège
University of Liège

Articles

304 Bulletin

Amélie Lamarcq, Sandrine Mathieu The EU Court of Justice clarifies the conditions under which pay-for-delay agreements preventing generic versions of a patented medicine from entering the market or delaying such entry may constitute a restriction of competition ‘by object’ or ‘by effect” as well as an abuse of dominant position (Generics - UK / GlaxoSmithKline / Actavis / Xellia Pharmaceuticals / Merck / Alpharma)

304

On 30 January 2020, the Court of Justice of the EU (‘CJEU’) ruled on the applicability of competition law to settlement agreements between a holder of a pharmaceutical patent and manufacturers of generic medicines. In a judgment issued only a week after Advocate General Kokott delivered her (...)

Send a message